HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer Drug Safety Dermatology

Consumer Industry Roundup: Catalent Acquires Accucaps; CHPA Adds Lobbyist; Zeasorb Recall

This article was originally published in The Pink Sheet

  • News

Executive Summary

Mylan's Schloss joins CHPA government affairs; Catalent expands softgel capabilities with Accucaps acquisition; GKSk recalls a half million bottles of mislabeled Zeasorb; and more news in brief.

You may also be interested in...



Taking GSK's Consumer Helm Gives McNamara View From Atop The OTC Space

Brian McNamara becomes GSK Consumer CEO after Emma Walmsley is named to succeed Andrew Witty in 2017 to run Glaxo.

OTC Industry News Roundup: Earnings, User Fee Webinar, UK Ad Enforce

Sensodyne shines for Glaxo-Novartis JV; and international growth leads Prestige Brands OTCs.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Table

View full table

Topics

Related Companies

Tags:
Consumer Drug Safety Dermatology
Latest Headlines

Cosmetic And Personal Care Trademark Review: 16 April

Health And Wellness Weekly Trademarks Review: 16 April

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Prestige Expands UK Eye Care Range In Response To Consumer Demand

See All
UsernamePublicRestriction

Register

RS122940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By